Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
15
01
2020
accepted:
24
04
2020
revised:
20
04
2020
pubmed:
12
5
2020
medline:
22
6
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T-cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment. Fifteen patients (median age 13 years; range 1-20 years) with a median potential follow-up of 39 months demonstrated 24-month cumulative incidence of relapse, cumulative incidence of TRM, and OS of 16% (95% CI: 0-37%), 20% (95% CI: 0-40%), and 80% (95% CI: 60-100%), respectively. Severe toxicity following CAR T cells did not impact OS (p = 0.27), while greater time from CAR T cells to allo-HSCT (>80 days) was associated with a decrease in OS. In comparing CD34-selected T-cell depleted (TCD; n = 9) vs unmodified (n = 6) allo-HSCT, the cumulative incidence of relapse, TRM, and OS at 24 months was 22% (95% CI: 0-49%) vs 0% (p = 0.14), 0% vs 50% [95% CI: 10-90%] (p = 0.02) and 100% vs 50% [95% CI: 10-90%] (p = 0.02). In this small cohort of patients, CAR T cells followed by a CD34-selected TCD allo-HSCT appears to result in less TRM and favorable OS when compared with unmodified allo-HSCT. There was no evidence that disease control was impacted by the type of consolidative allo-HSCT, which demonstrates the feasibility of this approach.
Identifiants
pubmed: 32390002
doi: 10.1038/s41409-020-0926-1
pii: 10.1038/s41409-020-0926-1
pmc: PMC7606268
mid: NIHMS1587859
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2160-2169Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. https://doi.org/10.3322/caac.21387 .
doi: 10.3322/caac.21387
pubmed: 28055103
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–9. https://doi.org/10.1200/JCO.2011.37.8018 .
doi: 10.1200/JCO.2011.37.8018
pubmed: 22412151
pmcid: 3383113
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52. https://doi.org/10.1056/NEJMra1400972 .
doi: 10.1056/NEJMra1400972
pubmed: 26465987
Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22:2142–50. https://doi.org/10.1038/leu.2008.251 .
doi: 10.1038/leu.2008.251
pubmed: 18818707
pmcid: 2872117
Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131:579–87. https://doi.org/10.1111/j.1365-2141.2005.05773.x .
doi: 10.1111/j.1365-2141.2005.05773.x
pubmed: 16351633
von Stackelberg A, Volzke E, Kuhl JS, Seeger K, Schrauder A, Escherich G, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer. 2011;47:90–97. https://doi.org/10.1016/j.ejca.2010.09.020 .
doi: 10.1016/j.ejca.2010.09.020
vCampana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013;162:147–61. https://doi.org/10.1111/bjh.12358 .
doi: 10.1111/bjh.12358
pubmed: 23654352
Shen Z, Gu X, Mao W, Yin L, Yang L, Zhang Z, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18:755 https://doi.org/10.1186/s12885-018-4670-5 .
doi: 10.1186/s12885-018-4670-5
pubmed: 30037340
pmcid: 6056932
Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2013;48:630–41. https://doi.org/10.1038/bmt.2012.139 .
doi: 10.1038/bmt.2012.139
pubmed: 22825427
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra225. https://doi.org/10.1126/scitranslmed.3008226 .
doi: 10.1126/scitranslmed.3008226
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl J Med. 2014;371:1507–17. https://doi.org/10.1056/NEJMoa1407222 .
doi: 10.1056/NEJMoa1407222
pubmed: 25317870
pmcid: 4267531
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. https://doi.org/10.1016/S0140-6736(14)61403-3 .
doi: 10.1016/S0140-6736(14)61403-3
pubmed: 25319501
Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018;16:664–6.
pubmed: 30543595
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31. https://doi.org/10.1182/blood-2017-02-769208 .
doi: 10.1182/blood-2017-02-769208
pubmed: 28408462
pmcid: 5482103
Curran KJ, Margossian S, Kernan NA, Silverman LB, Williams DA, Shukla NN, et al. Toxicity and response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. Blood 2019. https://doi.org/10.1182/blood.2019001641 .
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59. https://doi.org/10.1056/NEJMoa1709919 .
doi: 10.1056/NEJMoa1709919
pubmed: 29385376
pmcid: 6637939
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2019:1901892. https://doi.org/10.1200/JCO.19.01892 .
Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, et al. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019;3:3062–9. https://doi.org/10.1182/bloodadvances.2019000593 .
doi: 10.1182/bloodadvances.2019000593
pubmed: 31648329
pmcid: 6849954
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56. https://doi.org/10.1016/j.bbmt.2005.09.004 .
doi: 10.1016/j.bbmt.2005.09.004
pubmed: 16338616
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67. https://doi.org/10.7326/0003-4819-118-4-199302150-00003 .
doi: 10.7326/0003-4819-118-4-199302150-00003
pubmed: 8420443
Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107:4961–7. https://doi.org/10.1182/blood-2005-12-4942 .
doi: 10.1182/blood-2005-12-4942
pubmed: 16493003
pmcid: 1895819
Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, et al. Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica. 2008;93:925–9. https://doi.org/10.3324/haematol.12291 .
doi: 10.3324/haematol.12291
pubmed: 18413892
Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012;18:505–22. https://doi.org/10.1016/j.bbmt.2011.12.585 .
doi: 10.1016/j.bbmt.2011.12.585
pubmed: 22209888
Wood WA, Lee SJ, Brazauskas R, Wang Z, Aljurf MD, Ballen KK, et al. Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20:829–36. https://doi.org/10.1016/j.bbmt.2014.02.021 .
doi: 10.1016/j.bbmt.2014.02.021
pubmed: 24607554
pmcid: 4019683
Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265–74. https://doi.org/10.1200/JCO.2014.58.9747 .
doi: 10.1200/JCO.2014.58.9747
pubmed: 25753432
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024 .
doi: 10.1016/j.bbmt.2009.08.024
pubmed: 19766729
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758 .
doi: 10.1016/j.bbmt.2018.12.758
pubmed: 30592986
Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–9. https://doi.org/10.1182/blood-2007-06-093880 .
doi: 10.1182/blood-2007-06-093880
pubmed: 17717135
pmcid: 2234775
Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:1335–42. https://doi.org/10.1016/j.bbmt.2011.01.005 .
doi: 10.1016/j.bbmt.2011.01.005
pubmed: 21232623
pmcid: 3094599
Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19:208–13. https://doi.org/10.1016/j.bbmt.2012.09.003 .
doi: 10.1016/j.bbmt.2012.09.003
pubmed: 22982534
Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, et al. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 2015;50:493–8. https://doi.org/10.1038/bmt.2014.302 .
doi: 10.1038/bmt.2014.302
pubmed: 25621808
pmcid: 4382422
Shalabi H, Delbrook C, Stetler-Stevenson M, Yuan C, Steinberg S, Yates B, et al. Chimeric antigen receptor T-cell (CAR-T) therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant (HCT). Biol Blood Marrow Transplant. 2018;24. https://doi.org/10.1016/j.bbmt.2017.12.018
Perica K, Curran KJ, Brentjens RJ, Giralt SA. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24:1135–41. https://doi.org/10.1016/j.bbmt.2018.02.018 .
doi: 10.1016/j.bbmt.2018.02.018
pubmed: 29499327
pmcid: 6625528